News

Biotechnology startup Juvena Therapeutics Inc. has raised $41 million in new venture-capital funding to advance technology that could expand the range of treatments for chronic conditions and ...
Juvena has generated hits and new drug targets across several therapeutic areas. To learn more about Juvena Therapeutics, visit JuvenaTherapeutics.com or follow the company on LinkedIn @ Juvena ...
JUV-161 is a first-in-class muscle regenerating biologic that will address myopathies starting with Myotonic Dystrophy Type 1 JUV-161 was discovered using Juvena’s proprietary JuvNET platform ...
Juvena Therapeutics. Research will leverage world’s first AI-enabled screening platform for mapping the therapeutic potential of secreted signaling proteins, developed by Juvena ...
At BIO 2025, pharmaphorum Editor in Chief spoke with Hanadie Yousef, CEO of Juvena Therapeutics, a biotech focused on ...
About Juvena Therapeutics. Juvena Therapeutics is a computationally-driven biopharmaceutical company on a mission to develop disease-modifying biologics to treat chronic muscle and metabolic diseases.
Scientist-turned-entrepreneur steers efforts to transform approaches in tissue regeneration. (The story of Hanadie Yousef, PhD, co-founder and CEO of Juvena Therapeutics and a 2023 Emerging Pharma ...
Juvena Therapeutics Inc. co-founder and CEO Hanadie Yousef had the company’s name picked out several years before it was officially incorporated in 2017 to combine Yousef’s work in the mechanics of ...
Eli Lilly and Company (NYSE:LLY) is one of the best stocks to buy for beginners now. On June 11, Eli Lilly announced a partnership with Juvena Therapeutics to develop new muscle-boosting drugs.
REDWOOD CITY, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Juvena Therapeutics, Inc. (“Juvena”), a clinical-stage biotechnology company pioneering tissue restorative biologics for chronic muscle ...
JUV-161 is a first-in-class muscle regenerating biologic that will address myopathies starting with Myotonic Dystrophy Type 1 JUV-161 was discovered using Juvena's proprietary JuvNET platform, an ...